IMO Smedley should go bye bye next. not the right Chairman for a company like RSH. I think investors will not take someone with Smedley's track record seriously and it will hurt RSH moving forward and attracting new investors. didn't Smedley bankrupt a property company in Australia? The Australian roll out strategy was a complete failure, especially the failed acquisition of Adherium. I hope Access Health was a better acquisition? I'm not yet convinced. I hope I'm proven wrong
RSH Price at posting:
2.8¢ Sentiment: Sell Disclosure: Held
